{"id":"NCT01416636","sponsor":"SciPharm SÃ RL","briefTitle":"Efficacy and Tolerability of Subcutaneously Administered Treprostinil Sodium in Patients With Severe (Non-operable) Chronic Thromboembolic Pulmonary Hypertension (CTREPH)","officialTitle":"A Double Blind Controlled Clinical Study to Investigate the Efficacy and Tolerability of Subcutaneous Treprostinil Sodium in Patients With Severe Non-operable Chronic Thromboembolic Pulmonary Hypertension (CTREPH)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-03","primaryCompletion":"2016-11","completion":"2021-04","firstPosted":"2011-08-15","resultsPosted":"2019-06-10","lastUpdate":"2022-06-07"},"enrollment":105,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Non-operable Chronic Thromboembolic Pulmonary Hypertension"],"interventions":[{"type":"DRUG","name":"Treprostinil sodium","otherNames":[]}],"arms":[{"label":"Treprostinil sodium low dose - Arm I","type":"ACTIVE_COMPARATOR"},{"label":"Treprostinil sodium high dose - Arm II","type":"EXPERIMENTAL"}],"summary":"The primary purpose of this study is to determine the effect on six-minute walking test (6MWT) distance after 24 weeks treatment with subcutaneous (SC) Treprostinil Sodium in patients with Severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension.","primaryOutcome":{"measure":"Change in 6-minute Walk Test Distance After 24 Weeks","timeFrame":"Baseline and 24 weeks","effectByArm":[{"arm":"High Dose","deltaMin":45.43,"sd":71.29},{"arm":"Low Dose","deltaMin":3.83,"sd":56.21}],"pValues":[{"comp":"OG000 vs OG001","p":"0.002"},{"comp":"OG000 vs OG001","p":"0.0003"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":6,"countries":["Austria","Czechia","Germany","Poland"]},"refs":{"pmids":["8205686","15194182","15249497","12446266","30477763"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":53},"commonTop":["Infusion site pain","Infusion site reactions","Diarrhoea","Oedema peripheral","Headache"]}}